SYNTHETIC IMMUNOGEN

Abstract: The present invention concerns novel immunogens. These immunogens comprise novel compounds which consist of an antigen or antigenic determinant coupled to an amphiphilic adjuvant molecule and optionally also free amphiphilic adjuvant molecules. An advantageous feature of these novel immunogens is the presence of both an excellent immunogen activity as well as a pronounced adjuvant activity in a single complex.

Description: The invention relates to an immunogen consisting of at least one type of antigen or antigenic determinant coupled to a carrier; to a compound comprising an amphiphilic adjuvant; to methods for the preparation of, respectively, the immunogen and the compound comprising the amphiphilic adjuvant; as well as to pharmaceutical preparations possessing immunising activity and containing such an immunogen. In man and animals, an immuneresponse can be brought about by inoculating them with non-autologous antigens. This is utilised, in particular, in protecting man and animals against infections by pathogenic organisms such as viruses, bacteria, parasites and the like, but also in stimulating the production of antibodies against non-pathogenic substances, for example for the production of antisera for use in diagnostic tests, and for immunological sterilisation or castration. In general, such an active immunisation is carried out by inoculating the human subject or animal to be protected with inactivated or attenuated strains of the pathogenic organisms. A disadvantage of inoculation with inactivated material is that the immunising power is often low, as a consequence of the partial denaturation of the antigens which occurs during inactivation. Inoculation with attenuated strains entails the risk that the strains still possess a certain pathogenicity or that they become pathogenic again through spontaneous mutation. Hence, better alternatives are increasingly being sought. Inter alia, use is made, in this context, of immunogens which consist of antigens or antigenic determinants which are coupled to a carrier. In this way, even antigens or antigenic determinants which do not per se bring about an immune response can be made active as an immunogen. The numerous types of carriers which are used for this purpose have, in general, disadvantages which stand in the way of a general use, for example in man, such as toxicity and possible cross-reaction with endogenous substances. It is the object of the present invention to overcome such disadvantages. An immunogen according to the invention is characterized in that it consists in the main of a micelle of at least one type of amphiphilic adjuvant and that the antigens and/or the antigenic determinants are covalently coupled to at least a part of these amphiphilic adjuvants. The antigen and/or antigenic determinants in the immunogen according to the invention can, for example, be polypeptides, proteins, protein fragments, oligosaccharides or polysaccharides, oligonucleotides or polynucleotides or other antigenic compounds. For example, these may be derived from pathogenic organisms such as viruses, bacteria, parasites or the like, and may optionally comprise a fragment of an antigen originating from these organisms, or they may be prepared synthetically and correspond to natural antigens or antigenic determinants, or may be derived from these. The immunogens according to the invention can also comprise antigens or antigenic determinants which correspond to, for example, hormones or to hormone analogues or to particular drugs etc. Furthermore the antigen also may be an anti-idiotype antibody or a suitable fragment thereof. Such an anti-idiotype antibody mimics an antigen or antigenic determinant as to its relevant immunogenic property. The antigens and antigenic determinants can be isolated from biological or microbiological preparations and can thereafter be purified, if desired. They can, where appropriate, be obtained by splitting or fragmentation of larger molecules which are isolated from the abovementioned preparations. Furthermore, the antigens and antigenic determinants of low molecular weight, in particular, can advantageously be prepared by chemical synthesis. For example, this is very readily possible with small polypeptides, oligonucleotides and oligosaccharides. Such small, but in particular also larger, antigenic molecules can also be advantageously prepared with the aid of cell cultures or cultures of micro-organisms which contain a recombinant DNA which codes for the production of the particular molecule. It is also possible, with the aid of recombinant DNA techniques, to prepare antigenic molecules which, for example, contain a plurality of antigenic determinants which occur on different natural antigens which, for example, are derived from different pathogens or from variants of one and the same pathogen. By an antigenic determinant there is understood, in this context, a chemical structure which can form a recognition site for one or more types of antibodies directed against this recognition site. In this sense, an antigenic determinant can comprise one or more epitopes. By an antigenic determinant there is also understood a so-called hapten - an independently occurring chemical entity which, for example as a result of its relatively small dimensions, is incapable of functioning as an immunogen unless it is bound to a carrier. Specific examples of suitable amphiphilic adjuvants for use in the immunogens according to the invention are avridine (N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl)-propanediamine), the lipoidal amine 4-aminomethyl-1-(2,3-(di-n-decyloxy)-n-propyl)-4-phenylpiperidine, dimethyl-dioctadecylammonium bromide, lauryl-muramyl-dipeptide, lauryltetrapeptide (N²-[N-(N-lauryl-L-alanyl)-γ-D-glutamyl]-N⁶-(glycyl)-D,D-L,L-2,6-diaminepimelamic acid, L-tyrosine and alkyl derivatives thereof, maltose tetrapalmitate, pluronic polyols, L-tyrosine-azobenzene-p-arsonate, sorbitanmonooleate (Span 80), trehalose derivatives (such as trehalose dimycolate), retinoic acid and derivatives thereof, D;L-α-tocopherol (vitamin E), lipid A and analogues glycosides such as, for example, saponins (for instance Quil A from the bark of Quillaja saponaria Molina) and carbomers, such as Carbopol 934 (R) , Carbopol 940 (R) and Carbopol 941 (R) and copolymers of hydrofobic and hydrophylic phenyl-derivatives. The immunogen according to the invention comprises the molecular compound as described above, or a multitude of these molecules associated in e.g. micellar complexes, which can have various forms and/or dimensions. These micelles can be formed by interaction between identical amphiphilic adjuvants or by interaction between two or more types of different amphiphilic adjuvants. In the immunogen according to the invention, the antigens and/or antigenic determinants are covalently coupled to at least a part of the amphiphilic adjuvants. The nature of this coupling depends on the groups involved in this coupling, on, respectively, the amphiphilic adjuvants and the antigens and/or antigenic determinants, and on the nature of the particular reactive component itself. This coupling can be directly between the groups of, respectively, an antigen or antigenic determinant and the adjuvant molecular or indirectly through the presence of a so-called "linker" between the antigen and antigenic determinant and adjuvant molecule. An immunogen according to the present invention can consist of a micelle to which one type of antigen or antigenic determinant is coupled or of a micelle to which at least two different types of antigen and/or antigenic determinant are coupled. In this last case, the different types can be characteristic of a particular pathogen or of a substance against which immunisation is desired or, if required, different variants thereof, or of different unrelated types of pathogens and/or other substances against which immunisation is desired. The immunogen according to the invention can, if desired, be stabilised. Such stabilisation can for example be achieved by at least a portion of the antigens and/or antigenic determinants and/or at least a portion of amphiphilic adjuvants being linked to one another. Moreover, for stabilisation the immunogen, which may or may not be linked, can be used in an encapsulated form. Suitable capsules are, for example, those which are composed of polymers which can decompose in the body, such as polylactic acid, polyglycolic acid, mixed polymers of lactic acid and glycolic acid, polyamino acid, mixed polymers of lactic acid and one or more amino acids, or polymerized albumin. A number of alternative methods are available for the preparation of an immunogen according to the invention. For example, it is possible to start from compounds of at least one antigen and/or antigenic determinant with at least one amphiphilic adjuvant. The antigen and/or antigenic determinant, on the one hand, and amphiphilic adjuvant on the other, can if desired be joined together by one or more linkers. Such derivatives of amphiphilic adjuvants also form part of the invention. An immunogen according to the invention can be prepared from the abovementioned compounds by forming a micelle therefrom in a manner customary for compounds of this type, and thereafter isolating the immunogen. For this, it is possible to start from one type of compound which comprises at least one antigen and/or antigenic determinant and at least one amphiphile, but it is also possible to prepare an immunogen from a mixture of compounds with at least two different antigens and/or antigenic determinants. Preferably, the said micelles are prepared by ultrasonication of a solution which contains the abovementioned derivatives of amphiphilic adjuvants in a quantity equal to at least the critical micellar concentration. If desired, the adjuvant derivatives can be mixed with corresponding or different free amphiphilic adjuvants, and immunogens with mixed micelles, partially consisting of unbound adjuvant molecules, can be prepared therefrom. Another method for the preparation of an immunogen according to the invention is based on the covalent coupling of antigens and/or antigenic determinants in a manner customary per se for such coupling reactions, to a micelle which consists in the main of amphiphilic adjuvants, after which the immunogen is isolated. This coupling takes place through the reaction of reactive groups on the adjuvant micelle with reactive groups of the antigens and/or antigenic determinants. If desired, the amphiphilic adjuvants, antigens and/or antigenic determinants can be provided with linkers which contain reactive groups. Examples of suitable reactive groups are amine groups, carboxyl groups, hydroxyl groups, thiol groups, disulphide groups, carbonyl groups, maleimide groups and activated carboxyl groups. Regardless of the method of preparation, the immunogen can, if desired, also be stabilised (for example by mutual linking of the adjuvant molecules, antigens and/or antigenic determinants) and/or be protected against hydrolytic digestion (for example by encapsulating the immunogen, which may or may not be linked, in, for example, a polymer which can be decomposed in the body). The mutual linking of the adjuvants, antigenic determinants and/or amphiphilic adjuvants can be carried out with any reagent possessing at least two reactive groups which are suitable for reacting with the components to be linked. For the linking of polypeptides use is advantageously made, for example, of glutaraldehyde or formaldehyde, or of bifunctional reagents, such as homobifunctional reagents (bisamidates or bisuccinimidyl esters) or heterobifunctional reagents (for example compounds which possess an azidophenyl group and a maleimido, amidate, succinimidyl, haloketone or activated fluorobenzene group). Examples of polymeric materials which can be digested in the body and which are suitable for the encapsulation of the immunogen have already been mentioned above. Such materials can be applied onto or around the immunogen in a manner customary for this purpose. The immunogen according to the invention is in particular suitable for use in vaccines. Such a vaccine can inter alia be used for immunising man or animals against certain pathogens (viruses, bacteria, parasites and the like) or allergens, for so-called "priming" (wherein the body is not directly stimulated to form specific free antibodies but in fact is preconditioned so that after subsequent infection or revaccination a powerful immunising reaction is elicited), or, for example, for immunological sterilisation or castration (wherein antibodies directed against substances vital for the reproductive processes, such as certain hormones, are caused to be produced). The abovementioned vaccines can, if desired, comprise two or more different antigens and/or antigenic determinants which, for example, are coupled to one and the same micelle, or can comprise a mixture of two or more immunogens according to the invention, each of which itself comprises a certain type of antigen or antigenic determinant. The different antigens and/or antigenic determinants can be representative of different pathogens etc., or of variants of one and the same pathogen, etc. In order to be able to use an immunogen according to the invention for vaccination purposes the immunogen must be converted to a form suitable for the particular pharmaceutical administration. For intramuscular or subcutaneous administration the immunogen must be mixed with a suitable liquid, for example a physiological salt solution. For intranasal or intra-ocular administration, for example in the form of a spray, an aqueous medium is also the most suitable. For local, for example oral, administration it will in many cases be necessary to use an administration form wherein the immunogen is temporarily protected, for example against saccharolytic enzymes present in the oral cavity, or against proteolytic enzymes present in the stomach, or against detergents. Such protection can be achieved, for example, by encapsulating together one or more immunogens according to the invention in a suitable material, by incorporating the immunogen in a delayed-release and/or controlled-release administration form, or by chemically modifying, in polypeptide antigens and/or antigenic determinants, sites which are sensitive to proteolytic enzymes, in such a way that proteolytic cleavage is impossible or is greatly hindered. Example 1 Preparation of thiolated Quil A A. via reduction amination 45 mg of Quil A, purified beforehand on DEAE-Sephacel according to K. Dalagaard ("Saponin Adjuvants" Archiv fuer die gesamte Virusforschung 44, 243-254 (1974)) are dissolved in 0.8 ml of 0.1 mol/l sodium phosphate buffer of pH 8.0. The clear solution is diluted with 1.5 ml of methanol and then mixed with a solution of 60 mg of 2-(2-pyridyldithio)-ethylamine.HCl in 0.2 ml of the said phosphate buffer. 0.05 ml of a 1 mol/l solution of sodium cyanoborohydride in methanol is added, after which the reaction mixture is stirred for 20 hours at room temperature. After addition of 0.05 ml of acetic acid, the low molecular components are removed by gel filtration through Sephadex G-25 in 0.1 mol/l sodium phosphate buffer of pH 6.0, containing 5 mmol/l EDTA. Thereafter, dithioerythritol is added, until the concentration is 20 mmol/l, to the fraction containing Quil A. After 20 minutes at room temperature, the thiolated Quil A is isolated by gel filtration through Sephadex G-25 in the said phosphate/EDTA buffer. B. via amidation 10 mg of purified Quil A is dissolved in 0.2 ml of water and 0.2 ml of dimethylformamide. The pH of the solution is brought to 3-3.5 with 1 mol/l HCl, after which 6.0 mg of 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide.HCl are added, with stirring. After 3 minutes at room temperature, 7.0 mg of 2-(2-pyridyldithio)-ethylamine.HCl in 0.2 ml of 0.2 mol/l sodium phosphate buffer of pH 8.0 are added. The pH of the solution is brought to 8 by adding ethyldiisopropylamine. After 30 minutes, acetic acid is added until the pH is 5-6, after which the derivatised Quil A is isolated by gel filtration through Sephadex G-25 in 0.1 mol/l sodium phosphate buffer of pH 6.0, containing 5 mmol/l EDTA. The reduction with dithioerythritol and the isolation of thiolated Quil A are carried out as described under A . C. via activation with 2,2,2-trifluoroethanesulphonylchloride 50 mg of Quil A, purified as described under A, are dissolved in dry pyridine, after which the solution is evaporated in vacuo. This procedure is repeated once. The Quil A thus obtained is subsequently suspended in dry dioxane (0.5 ml), after which 8 µl of 2,2,2-trifluoroethanesulphonyl chloride are added with vigorous mixing. After having been stirred for 10 minutes at room temperature, the mixture is diluted with 5 ml of 0.05 mol/l HCl, which has beforehand been cooled to 4 °C, and is then dialysed for 5 hours against 0.01 mol/l HCl (2 x 1 litre) at 4 °C. A solution of 40 mg of 2-(2-pyridyldithio)-ethylamine.HCl in 1 ml of 0.5 mol/l sodium phosphate buffer of pH 8.0 is added to the resulting solution of Quil A at 4 °C. The pH is brought to 8.0 by adding NaOH, after which the mixture is stirred for 18 hours at 4 °C. The derivatised Quil A is isolated by gel filtration through Sephadex G-25 in 0.2 mol/l phosphate buffer of pH 6.0 containing 5 mmol/l EDTA. The reduction with dithioerythritol and isolation of the thiolated Quil A are carried out as described under A. Example 2 β-endorphin-(6-17)-immunogen.I A. Preparation of activated avridine 1.67 g (25 mmol) of N,N-dioctadecyl-N',N'-bis-(2-hydroxyethyl)-propanediamine [avridine: CP 20961] are added to a solution of 2.82 g (10 mmol) of trifluoromethanesulphonic anhydride in 20 ml of methylene chloride. 0.4 ml (5.2 mmol) of pyridine is added, after which the mixture is stirred for 60 minutes at room temperature. A solution of 2.5 g (32 mmol) of thiolacetic acid in water, brought to pH 7.5 with NaOH, is then added. The two-phase system is stirred vigorously for 60 minutes. The methylene chloride layer is separated off, dried over MgSO₄ and evaporated. The residue is recrystallised from methylene chloride/ether. The S-acetyl derivative of avridine, in methylene chloride, is mixed with avridine (1:1). The solvent is evaporated off and the residue is dispersed (5 mg/ml) in 0.1 mol/l sodium phosphate buffer of pH 7.0, containing 0.1 mol/l NaCl and 0.05 mol/l EDTA. The dispersion is ultrasonicated under N₂ for 5 minutes at 60 °C [Branson Sonifier; microtip, 20 W]. B. Preparation of β-endorphin-(6-17)-immunogen Deoxygenated 0.5 mol/l hydroxylamine of pH 7.2 is added, to a final concentration of 0.04 mol/l, to a solution of derivatised avridine prepared according to Example A. The mixture is kept for 30 minutes at 35 °C in an N₂ atmosphere. Thereafter there is added, at 20 °C, a solution of 1.5 equivalents, relative to the thiolated avridine, of a maleimide derivative of β-endorphin-(6-17) dissolved in 0.1 mol/l sodium phosphate buffer of pH 6.0, containing 0.005 mol/l EDTA. The mixture is stirred for 15 hours under N₂ and then dialysed against an 0.05 mol/l sodium phosphate buffer of pH 7.4, which contains 0.1 mol/l NaCl. Example 3 β-endorphin-(6-17)-immunogen. II To a solution of thiolated Quil A (7 mg/ml), prepared according to 1A, are added 1.2 mole-equivalents (based on the thiol groups) of a maleimide derivative of β-endorphin-(6-17), namely in 0.1 mol/l phosphate buffer of pH 6.0, containing 5 mmol/l EDTA. This mixture is allowed to react for 1 hour at room temperature and thereafter is dialysed for 15 hours at 0 °C against 0.02, mol/l sodium phosphate buffer of pH 7.4, which contains 150 mmol/ml NaCl. Example 4 Parvovirus immunogen A. Preparation of porcine parvovirus antigen A 65 kD coat protein of porcine parvovirus (PPV) is isolated in accordance with the procedure described by Molitor, T.W., Joo, H.S. and Collet, M.S.: J. Virology 45 , 842-854 (1983): a concentrated CaCl₂ solution is added to a PPV-containing tissue culture supernatant until the CaCl₂ concentration is 25 mmol/l; the virus precipitate thereby formed is centrifuged for 20 minutes at 12,000xg; the virus-containing pellet is then centrifuged in a CsCl gradient; the fraction of density 1.3 g/ml is isolated, dialysed and then treated for 3 minutes with 1% sodium dodecyl sulphate (SDS); and the 65 kD protein is isolated by SDS/PAGE fractionation, dialysed and freeze-dried. B. Derivatisation of porcine parvovirus antigen The protein obtained under A. is dissolved in 0.1 mol/l sodium phosphate buffer of pH 7.5 to a concentration of 3 mg/ml, and is then treated with 5 mole-equivalents of N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) for 30 minutes at room temperature. The excess SMCC is removed by gel filtration through Sephadex G-25 in 0.1 mol/l sodium phosphate buffer of pH 6.0, which contains 0.9% NaCl and 5 mmol/l EDTA. C.Preparation of immunogen The derivatised PPV coat protein obtained by B. is mixed with thiolated Quil A, prepared according to Example 1A, in a ratio of 1:4 (Quil A:protein) (weight/weight). The solution is kept for 5 hours at room temperature after which the immunogen is isolated by centrifuging it in a 10-40% (weight/weight) sucrose gradient at 250,000xg for 10 hours at +4 °C. The PPV immunogen is subsequently dialysed against 0.02 mol/l phosphate buffer of pH 7.4, which contains 150 mmol/l NaCl. Example 5 Parvovirus peptide immunogen The maleimide derivative of the peptide: (obtained from AMGen), which corresponds to a part sequence of a PPV coat protein, is coupled, in the manner described under Example 3, to thiolated Quil A. Example 6 HBsAg immunogen A polypeptide derived from HBsAg (hepatitis B surface antigen), wherein the amino-terminal hydrophobic portion is absent, is prepared according to a method described by Fujisawa et al. (Nucleic Acids Research 11 , 3581-3590 (1983)) in E. coli. After extraction from these bacteria, the polypeptide is purified by means of affinity chromatography. The purified HBsAg derivative is activated, before the coupling to adjuvant, by means of SMCC as described under Example 4B. The activated polypeptide is subsequently coupled to thiolated Quil A analogously to the method described under Example 4C. Example 7 Parvovirus immunogen A. Preparation of thiolated Quil A Quil A (20 mg) is dissolved in dimethylformamide (0.5 ml). Following the addition of HCl (10 µmoles; 1 N solution in DMF) and cooling of the solution at 0 °C, carbonyldiimidazole (20 µmoles in 0.04 ml DMF) is added. The reaction mixture is stirred at 0 °C for 30 minutes. 2-(2-pyridyldithio)-ethylamine.HCl (50 µmoles) and ethyldiisopropylamine (50 µmoles) are then added. The resulting clear solution is kept at room temperature for 18 hours. DMF is removed by rotary evaporation in vacuo and the resulting syrup is then dissolved in water (2 ml). Derivatized Quil A is isolated by gel filtration on Sephadex G-25 in 0.1 mol/l sodiumphosphate, pH 6.0, also containing 5 mmol/l EDTA. Thiolated Quil A is obtained following reduction with dithioerythritol and gel filtration on Sephadex G-25 as described under Example 1A. B. Preparation of derivatized porcine-parvovirus antigen A solution of the parvovirus protein (2 mg), isolated as described under Example 4A, in 0.1 mol/l sodiumphosphate, pH 7.6, is treated with N-succinimidyl 3-(2-pyridyldithio)-propionate (SPDP; 3.2 µmoles in 0.3 ml ethanol) for 3 hours at room temperature. The 2-pyridyldisulfide substituted protein is isolated by gel filtration on Sephadex G-25 in 0.1 mol/l sodiumohosphate, pH 6.0, also containing 5 mmol/l EDTA. C. Preparation of the immunogen A solution of thiolated Quil A (containing 0.6 µmol of free thiol groups), obtained as described under A, is added to a solution of 2-pyridyldisulfide-substituted porcine parvovirus protein (containing 0.45 µmoles at 2-pyridyldisulfide groups), obtained as described under B. The coupling reaction, which is monitored by measuring the release of pyridine-2-thion, is completed within 2 hours. The Quil A-protein conjugate is subsequently dialysed against 0.02 mol/l sodiumphosphate, pH 7.4, also containing 150 mmol/l NaCl. - Example 8 Efficacy of immunogen Two groups of 10 six weeks old Swiss albino mice were repeatedly inoculated i.p. with a rabies virus coat-peptide coupled to either KLH or Quil A. This peptide has the amino acid sequence Asp-Tyr-Arg-Trp-Leu-Arg-Thr-Val-Lys-Thr-Thr-Lys-Gly-Ser. Doses of 50 µg of the above peptide bonded either to 50 µg of Quil A or to 500 µg Of KLH were repeatedly inoculated in each of the mice. Sera from these mice, diluted 1/80, were tested by enzyme-labeled immunosorbent assay (ELISA) after the third and the fourth inoculation using the following respective test systems: after third inoculation: virus-coated micro-titration plates - mouse serum -anti-mouse Ig-HRP-conjugate after fourth inoculation: micro-titration plates coated with human anti-rabies monoclonal antibodies - ERA-virus antigen - mouse serum -anti-mouse-Ig-HRP-conjugate. The results are summarized in the following table. The above results indicated that antibodies raised against the Quil A-peptide complex show excellent virus binding - at least as good as the virus binding by antibodies raised against KLH-peptide complexes. Example 9 Adjuvant effect of saponine derivatives Four groups of 10 nine weeks old Swiss albino mice were i.m. inoculated with Pseudorabies (PR) antigen as such or together with the adjuvant to be tested. After 3, 9 and 15 weeks sera were collected and pooled to be tested as to anti-PR response in an enzyme-linked immunosorbent assay (ELISA). The results are summarized in the following table. The above results indicate that the adjuvant activity of Quil A remains intact after derivatizing the adjuvant, and even after coupling of the peptide.

Claims: Immunogen comprising at least one type of antigen and/or antigenic determinant, coupled to a carrier, characterised in that the carrier essentially consists of a micelle of at least one type of amphiphilic adjuvant molecules, at least a portion of said molecules being covalently coupled to the antigens and/or antigenic determinants. Immunogen according to claim 1, characterised in that the antigens and/or antigenic determinants are coupled to the amphiphilic adjuvant molecule by means of at least one linker. Immunogen according to claim 1 or 2, characterised in that it contains saponins as amphiphilic adjuvants. Immunogen according to claims 1-3, characterised in that it contains different types of antigens and/or antigenic determinants, which are characteristic for different types of pathogens and/or other substances against which immunisation is desired. Immunogen according to claims 1-4, characterized in that at least a portion of the antigenic determinants and/or antigens and/or the amphiphilic adjuvant molecule is/are linked to one another. Immunogen according to claims 1-5, characterised in that it is encapsulated. Immunogen comprising a multitude of compounds associated in a complex which can have various forms and/or dimensions said multitude of compounds containing at least one type of amphiphilic adjuvant molecules, at least a portion of said molecules being covalently coupled to an antigen and/or antigenic determinant. Immunogen according to claim 7, characterised in that the antigen and/or antigenic determinant, on the one hand, and the amphiphilic adjuvant molecule, on the other, are linked to one another by at least one linker. Process for the preparation of an immunogen according to claims 1-6, characterised in that a micelle is formed, in the manner customary for the purpose, from at least one type of compound containing an amphiphilic adjuvant molecule and an antigen and/or antigenic determinant being covalently coupled to one another, if desired in the presence of at least one type of free amphiphilic adjuvant, and thereafter the immunogen is isolated, after which the immunogen is, if desired, stabilised and/or protected against hydrolytic cleavage. Process for the preparation of an immunogen according to claims 1-6, characterised in that antigens and/or antigenic determinants, if desired, provided with at least one linker, are allowed to react, in a manner known per se, with micelles which, if desired, are provided with one or more linkers and which in the main consist of at least one type of amphiphilic adjuvant, thereby producing a covalent coupling between the said antigens and/or antigenic determinants or linkers which may be linked thereto, on the one hand, and the said amphiphilic adjuvants or linkers which may be linked thereto, on the other hand, and that thereafter the immunogen is isolated, after which it is, if desired, stabilised and/or protected against hydrolytic cleavage. Pharmaceutical preparation having an immunising action, characterised in that it contains at least one immunogen according to claims 1-8. Pharmaceutical preparation according to claim 11, characterised in that it contains a plurality of the said immunogens in a delayed-release dosage form, Pharmaceutical preparation according to claim 11 or 12, characterised in that it contains two or more different types of the said immunogens.

Inventors: BOON, PETRUS JOHANNES, VISSER, NICOLAAS
Applicants: AKZO N.V.
Application year: 1986
Main classification: A61K39
IPC codes: A61K39, A61K47, A61K9